The effect of computerized physician order entry on medication errors and adverse drug events in pediatric inpatients

W James King1, Naomi Paice, Jagadish Rangrej

  • 1Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada. king@cheo.on.ca

Pediatrics
|September 2, 2003
PubMed

Insights

Computerized physician order entry (CPOE) significantly reduced medication errors in pediatric inpatients. However, the study found no significant impact on adverse drug events (ADEs) after CPOE implementation.

Area of Science:

  • Health Informatics
  • Pediatric Patient Safety
  • Medication Error Reduction

Background:

  • Medication errors pose a significant risk to patient safety, particularly in pediatric populations.
  • Computerized physician order entry (CPOE) systems are designed to mitigate these risks by improving the accuracy and legibility of medical orders.
  • Assessing the real-world impact of CPOE on medication errors and adverse drug events (ADEs) is crucial for optimizing healthcare delivery.

Purpose of the Study:

  • To evaluate the effectiveness of a commercially available CPOE system in reducing medication errors and ADEs among pediatric inpatients.
  • To compare medication error rates and ADEs in wards utilizing CPOE versus those relying on handwritten orders.

Main Methods:

  • A retrospective cohort study was conducted at a tertiary care pediatric hospital.
  • Data were collected from pediatric inpatients across medical and surgical wards over a 6-year period.
  • Medication error rates and ADEs were compared before and after the implementation of CPOE on specific wards.

Main Results:

  • The overall medication error rate (MER) was 4.49 per 1000 patient days.
  • Following CPOE implementation, MER decreased by 40% on intervention wards compared to control wards (ratio = 0.60).
  • No significant reduction in ADEs was observed with CPOE implementation (ratio of rate ratios = 1.30).

Conclusions:

  • The introduction of a CPOE system was associated with a significant decrease in medication errors in pediatric inpatients.
  • CPOE did not demonstrate a significant impact on reducing adverse drug events in this patient population.
  • Further research may be needed to explore strategies for optimizing CPOE to also reduce ADEs.
Abstract

Related Concept Videos

Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...